GrowerNottaShowER

HEALIGHT PATENT approval 11/23

NASDAQ:AYTU   Aytu BioPharma, Inc.
The most bearish of tickers but things change... sometimes very quickly

The HL device will have a huge impact in reducing the length of hospital stays due to VAP and other respiratory illnesses as well as a number of benefits for its outpatient potential. Hint: when hospitals and insurance companies can save billions of dollars of the tech, especially when world wide respiratory illness is the biggest problem, BIG BIG POTENTIAL!

The data behind the Healight Device is exceptional and there's one reason this has been brought down so brutally: CEDAR SINAI does not have the technology patented yet.

That changes on 11/23/21 when the patent will be officially issued.

The Data.... You really gotta dig in and review it because AYTU sure is tight lipped about it. But the technology is very impressive. Cedar Sinai confidentiality agreement? Very likely

Bag holder central and a gold mine for shorts the past year? ABSOLUTELY!

I can't blame it all on the CEO's inability to create shareholder value or the hedge Armistice capital LLC for.... well, playing Armistice with the SP, keeping it from delisting or letting the SP get out of hand before Cedars invests. Because Cedars will invest.... when the patent is issued in their name

Its a likely requirement of the company upon acquiring the licensing rights for respiratory illnesses to the HL device to do two things:
1: get everything inline and ready
2: Keep the SP inline with the timeline without it getting delisted or being too expensive (enter Armistice an agreement made by opposing sides in a war to stop fighting for a certain time; a truce)

As of now AYTU is already undervalued, even with its mediocre pipeline. but were here for Healight. ER 11/15 probably wont do much but if it does pop, dont expect much besides an offering. GL
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.